News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory Multiple Myeloma
Sikander Ailawadhi/mayoclinic.org
Dec 9, 2024, 14:30

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory Multiple Myeloma

Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a article by Sikander Ailawadhi on X:

“Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.”

Title: Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Authors: Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesús Berdeja, Sergio Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa McKiver and Paula Rodríguez-Otero

Ide-cel

Ide-cel

More posts featuringMohamed Benlazar.

 

 

Bertrand Arnulf cancer Krina Patel Michele Cavo Mihaela Popa-Mckiver Mohamed Benlazar multiple myeloma OncoDaily Oncology Paula Rodriguez-Otero Sidi Bel Abbès University Sikander Ailawadhi
Special Coverage
Insight
Dec 9, 2024, 14:30
Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory Multiple Myeloma
Insight
Dec 9, 2024, 14:27
Sanjay Popat: The Pan-Asian adapted ESMO Clinical Practice Guidelines for Oncogene Addicted Metastatic NSCLC
Blog
Dec 9, 2024, 14:25
Christine Lovly: Striving to overcome MRD observed with Targeted Therapy in Lung Cancer
Blog
Dec 9, 2024, 14:21
Omali Pitiyarachchi: Prof Zarnie Lwin – updates in the treatment of gliomas
Insight
Dec 9, 2024, 14:15
S2013 and S1501 Reopen for Enrollment with Key Protocol Updates
Blog
Dec 9, 2024, 14:13
Overview and clarification of the current HR+ HER2- EBC treatment landscape - SPCC
Dialogues
Dec 9, 2024, 14:11
Infantile Fibrosarcoma - Sarcoma Talk #10 with Daniel Orbach
Blog
Dec 9, 2024, 14:03
Abnormal prenatal blood test results could indicate hidden maternal cancers
Blog
Dec 9, 2024, 14:01
Fumiko Ladd Chino: Our HCW vs Hunger team is multiD this year from the get go
Blog
Dec 9, 2024, 13:43
Drew Moghanaki: The phase III KEYNOTE-867 study results at ESMO 2024
Blog
Dec 9, 2024, 13:36
Zhen Su: Overcome PD-1 Resistant in Solid Tumor with a Novel Dual T-cell Agonist approach
Blog
Dec 9, 2024, 13:27
NCD Alliance - Human rights offer protection ensuring everyone everywhere can live in dignity and respect